Minerva Neurosciences NASDAQ NERV Scores Up to $200M Funding Boost for Roluperidone Phase 3 Trial

Basio badr

ago 3 hours

Minerva Neurosciences NASDAQ NERV Scores Up to $200M Funding Boost for Roluperidone Phase 3 Trial

Minerva Neurosciences, Inc. (NASDAQ: NERV) has secured funding to support the clinical development of its treatment for schizophrenia. The company has announced a private placement that will provide up to $200 million in gross proceeds for advancing roluperidone, which targets the negative symptoms of schizophrenia.

Funding Details

The financing comprises several components:

$80 million in upfront capital through the issuance of Series A preferred stock.
Up to an additional $80 million from the exercise of Tranche A warrants.
$40 million contingent on achieving specific milestones through Tranche B warrant exercises.

Use of Proceeds

The funds raised will be utilized for multiple key objectives:

To finance the confirmatory Phase 3 trial for roluperidone.
To prepare for the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
To ensure commercial readiness in the United States, pending approval.

Timeline and Expectations

Closing of the private placement is projected for around October 23, 2025. Minerva aims to finalize its funding to adequately support the clinical trial and NDA resubmission processes.

Board of Directors Enhancement

As part of the funding agreement, Minerva intends to expand its board of directors by adding up to three investor-designated directors. These new board members are expected to bring valuable experience in clinical trials related to schizophrenia, further reinforcing the focus on clinical operations.

Significance of Roluperidone

Roluperidone addresses a critical unmet need in schizophrenia treatment, specifically targeting the debilitating negative symptoms. Current antipsychotic medications do not adequately treat these symptoms, which include emotional blunting and lack of motivation. The successful development of roluperidone could significantly improve the quality of life for many patients.

Future Developments

Minerva is also confirmed to be aligned with the FDA on the clinical development path for roluperidone. This collaboration aims to mitigate risks and enhance the likelihood of successful trial outcomes. The company anticipates further updates regarding trial enrollment and detailed timelines for the NDA resubmission in the coming months.

Conclusion

This strategic financing initiative positions Minerva Neurosciences to advance its promising treatment for schizophrenia. The additional resources and experienced board members are expected to enhance the company’s operational capabilities as it strives to meet regulatory and clinical milestones.